DFTXDefinium Therapeutics Inc. Common Shares

Key Takeaways; Cannabis Sector Curaleaf Holdings Announced Intention to Launch a Hostile Takeover Bid to Acquire Aurora Cannabis Organigram Posted Record Quarter as Sanity Group Acquisition Fueled Global Expansion Key Takeaways; Psychedelic Sector Optimi Health Set Up US$100 Million Equity Facility to Support Growth Definium Therapeutics’ Phase 3 Trial Delivered Strong Results for DT120 in […]

Definium Therapeutics (DFTX) is back in focus after reporting positive topline results from its Phase 3 Voyage study of DT120 ODT in generalized anxiety disorder. This event has quickly refocused attention on the stock. See our latest analysis for Definium Therapeutics. Definium Therapeutics has been highly volatile over the past year, with the latest share price at $43.90 following a 1 day share price return of 2.59% after the Voyage update. Despite recent 7 day and 30 day share price...

In August 2026, Definium Therapeutics reported that its Phase 3 Voyage trial of DT120 ODT in generalized anxiety disorder met the primary HAM-A endpoint and all key secondary measures, delivering rapid, statistically significant symptom reductions with a generally well-tolerated safety profile and no new safety signals identified. Beyond the headline efficacy, the data point to a single 100 µg dose producing early-onset, sustained relief over 12 weeks, highlighting how Definium’s LSD-based,...

Definium Therapeutics (NasdaqGS: DFTX) reported positive topline data from its pivotal Phase 3 Voyage trial of DT120 ODT in adults with generalized anxiety disorder. The study met all primary and key secondary endpoints, with results indicating significant efficacy alongside a positive safety and tolerability profile. DT120 ODT, an LSD based oral dissolving tablet, holds Breakthrough Therapy designation and is now positioned for potential regulatory review in a major psychiatric...

Definium Therapeutics' (DFTX) phase 3 data for DT120 in generalized anxiety disorder looked better t

Definium Therapeutics (NASDAQ:DFTX) reported positive top-line results from Voyage, its Phase III study evaluating a single 100 mcg dose of DT120 ODT for generalized anxiety disorder, or GAD. The company said the trial met its primary endpoint and all key secondary endpoints, showing rapid and durab

Definium Therapeutics unveiled the second of two positive Phase 3 studies for its LSD-based drug. The biotech stock rose on the results.

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index up 0.2% and t

Voyage is the company’s second successful late-stage readout for DT120, following positive results in major depressive disorder in June.

The S&P 500 Index and Nasdaq Composite were up slightly, while the Dow Jones Industrial Average was

Shares of Definium Therapeutics jumped more than 10% Wednesday morning after the biotech company said its experimental psychedelic drug helped reduce anxiety. DT120, a fast-dissolving tablet form of lysergide, was tested in a late-stage trial of 214 people with generalized anxiety disorder. Definium is also testing DT120 as a treatment for post-traumatic stress disorder.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.2%, and the actively tra

Definium Therapeutics (NASDAQ:DFTX) shares jumped 20% in premarket trading on Wednesday after the company announced positive topline results from its Phase 3 Voyage study evaluating DT120 ODT in patients with generalised anxiety disorder. The trial achieved its primary endpoint as well as all key secondary efficacy endpoints, providing another positive late-stage clinical result for the company’s DT120 ODT development programme.

Results from a late-stage study focused on generalized anxiety disorder were a “clean win” to analysts, who believe Definium has a drug with multibillion-dollar sales potential.

Definium Therapeutics, which develops treatments for mental health conditions, faces high expectations for its late-stage Voyage study of DT120.

Definium Therapeutics Inc (DFTX) reports the largest treatment effect ever seen in a Phase III MDD study while advancing its GAD program toward imminent top-line data.

Definium Therapeutics (NASDAQ:DFTX) said it expects to report top-line results from its Phase III VOYAGE study of DT120 ODT in generalized anxiety disorder during the week of Aug. 10, following positive Phase III results in major depressive disorder reported in June. Chief Executive Officer Rob Bar

The average of price targets set by Wall Street analysts indicates a potential upside of 34.9% in Definium Therapeutics, Inc. (DFTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Meridian Funds, managed by ArrowMark Partners, released its second-quarter 2026 investor letter for “Meridian Small Cap Growth Fund”. A copy of the letter can be downloaded here. The U.S. market saw a strong rally in the second quarter, fueled by easing geopolitical tensions, falling oil prices, and robust corporate earnings. Growth stocks, especially in technology and […]

Wells Fargo began coverage on five biotech stocks on Monday, with only Compass Pathways receiving an ‘Equal-Weight’ rating while the rest received ‘Overweight’ ratings.

Watch Fireside Chat Below, or Click HERE: IPO Edge hosted a fireside chat with Jupiter Neurosciences, Inc. (Nasdaq: JUNS) Chairman, Chief Executive Officer and Co-founder Christer Rosén and Alison Silva, […]

Definium Therapeutics (DFTX) stock is drawing fresh attention after the company published a large healthcare claims analysis on generalized anxiety disorder, highlighting frequent treatment switching, early discontinuation, and long gaps in care with existing therapies. See our latest analysis for Definium Therapeutics. The recent healthcare claims study comes as Definium Therapeutics stock continues a strong run, with a 30 day share price return of 84.15% and a year to date share price...

Earlier this month, Definium Therapeutics reported results from a large U.S. healthcare claims study of more than 1.27 million adults with generalized anxiety disorder, showing high rates of treatment discontinuation, rapid switching, and prolonged gaps in pharmacotherapy despite guideline recommendations. The study, published in CNS Spectrums, underscores how fragmented guidance, frequent comorbid depression, and limited innovation since 2007 leave a substantial unmet need for...

Billionaire investors such as Peter Thiel and Christian Angermayer are believers in the benefits of using psychedelics derived from magic mushrooms...

We recently compiled a list of the 7 Best Psychedelic Stocks to Buy According to Analysts. Definium Therapeutics, Inc. (NASDAQ:DFTX) is one of the best psychedelic stocks on our list. TheFly reported on June 30 that Canaccord reduced its price target on DFTX to $58 from $60 while reaffirming a Buy rating on the shares. The firm […]

An obscure psychedelic is drawing intense interest from the pharmaceutical industry. WSJ explores why companies are betting hundreds of millions of dollars on the therapeutic potential of a toad poison.

The average of price targets set by Wall Street analysts indicates a potential upside of 32.4% in Definium Therapeutics, Inc. (DFTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.